Focus on a platform-based business conducting joint research with multiple pharmaceutical companies
First written in FY2023. 4 of 8 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「Against this backdrop, in our platform business we used the enhanced aibVIS drug-discovery platform to advance the creation of mRNA-targeted small-molecule drugs through joint drug-discovery research with Toray Industries, Inc., Shionogi & Co., Ltd., RaQualia Pharma Inc. and Takeda Pharmaceutical Company Limited, with each project progressing smoothly. The joint research with Takeda Pharmaceutical Company Limited had already produced certain results, but following discussions and consideration by both companies, it ended in April 2026. Meanwhile, with Switzerland-based SpiroChem AG, with which we agreed in December 2025 to conduct joint exploratory research on mRNA-targeted compounds, we held repeated discussions on the details of the joint research and entered into an agreement in May 2026.」
While continuing the aibVIS-based platform business, the company’s partner base changed through the conclusion of joint research with Takeda Pharmaceutical Company Limited and the signing of a joint exploratory research agreement with SpiroChem AG. - 2026-05-11AdvancedBusiness Alliances
「The joint exploratory research aims to create state-of-the-art, world-leading small-molecule drugs targeting mRNA by combining SpiroChem's world-class expertise in compounds such as macrocycles, peptides and peptoids with VIS's AI-driven mRNA-targeted drug discovery platform aibVIS and cell-based experimental technologies.」
The joint exploratory research with SpiroChem advanced to a specific project combining aibVIS with SpiroChem's expertise in compounds following execution of the agreement. - FY2025RestatedAnnual report
「To deliver more mRNA-targeted small-molecule drugs to society more quickly, we operate a platform business that conducts numerous joint drug-discovery projects simultaneously with multiple pharmaceutical companies, using the highly versatile aibVIS platform as a strength in meeting the broad needs of pharmaceutical companies.」
The platform business continues to advance numerous joint drug-discovery projects with multiple pharmaceutical companies using the aibVIS platform. - 2026-03-02AdvancedGeneral Meetings of Shareholders
「Amid these changes, we aim to begin new joint drug discovery research on small-molecule drugs with Japanese and European pharmaceutical companies, and to collaborate with biotech companies that have a strong interest in drug discovery. In addition, because our technology can be applied to agrochemicals and major companies are eager to develop them, we intend to pursue contracts in the agrochemical field as well, seeking to improve future profitability.」
The company indicated a policy of expanding its collaboration and contracting targets beyond existing joint drug discovery research with pharmaceutical companies to include Japanese and European pharmaceutical companies, biotech companies and the agrochemical field. - FY2025-H1AdvancedAnnual report
「During the interim accounting period, we newly entered into a joint research agreement with Mitsubishi Gas Chemical Company, Inc.」
In addition to joint research with the existing 4 companies, the company entered into a new joint research agreement with Mitsubishi Gas Chemical Company, Inc. for its ibVIS® platform business. - FY2024-H1RestatedAnnual report
「In our mRNA-targeted small-molecule drug-discovery business, we are advancing joint drug-discovery research with Toray Industries, Inc., Shionogi & Co., Ltd., RaQualia Pharma Inc. and Takeda Pharmaceutical Company Limited, using the ibVIS® drug-discovery platform. To secure additional partners, we have approached pharmaceutical companies in Japan and overseas that are interested in mRNA-targeted small-molecule drug discovery, including by introducing our platform technology. Hereinafter, these pharmaceutical companies are collectively referred to as “partners.”」
The company continues joint drug-discovery research with 4 companies using ibVIS® and continues introducing its platform technology to pharmaceutical companies in Japan and overseas. - FY2024-Q1RestatedAnnual report
「During the cumulative first-quarter period, we operated a platform business focused on creating mRNA-targeted small-molecule drugs through joint drug-discovery research with pharmaceutical companies, using the ibVISⓇ drug-discovery platform.」
The company continues to operate a platform business conducting joint research with pharmaceutical companies using ibVIS®. - FY2023First statedAnnual report
「Rather than operating a pipeline business that holds a small number of in-house pipelines, we operate a platform business in which we use our proprietary drug-discovery platform, ibVIS®, to conduct joint drug-discovery research with multiple pharmaceutical companies.」
The core business model is to provide the proprietary platform to multiple pharmaceutical companies, rather than develop a small number of in-house pipelines.